Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer

Derek Jonker, Christos Karapetis, Christopher Harbison, Chris O'Callaghan, D Tu, R. Simes, Daniel Malone, Christiane Langer, Niall Tebbutt, Timothy Price, Jeremy Shapiro, L Siu, R Wong, Georg Bjarnason, Malcolm Moore, John Zalcberg, Shirin Khambata-Ford

    Research output: Contribution to journalArticle

    49 Citations (Scopus)

    Abstract

    Background:Anti-EGFR antibody, cetuximab, improves overall survival (OS) in K-ras wild-type chemotherapy-refractory colorectal cancer. Epidermal growth factor receptor ligand epiregulin (EREG) gene expression may further predict cetuximab benefit.Methods:Tumour samples from a phase III clinical trial of cetuximab plus best supportive care (BSC) vs BSC alone (CO.17) were analysed for EREG mRNA gene expression. Predictive effects of high vs low EREG on OS and progression-free survival (PFS) were examined for treatment-biomarker interaction.Results:Both EREG and K-ras status were ascertained in 385 (193 cetuximab, 192 BSC) tumour samples. Within the high EREG and K-ras wild-type status ('co-biomarker')-positive group (n=139, 36%), median PFS was 5.4 vs 1.9 months (hazard ratio (HR) 0.31; P<0.0001), and median OS was 9.8 vs 5.1 months (HR 0.43; P<0.001) for cetuximab vs BSC, respectively. In the rest (n=246, 64%), PFS (HR 0.82; P=0.12) and OS (HR 0.90; P=0.45) were not significantly different. Test for treatment interaction showed a larger cetuximab effect on OS (HR 0.52; P=0.007) and PFS (HR 0.49; P=0.001) in the co-biomarker-positive group.Conclusion:In pre-treated K-ras wild-type status colorectal cancer, patients with high EREG gene expression appear to benefit more from cetuximab therapy compared with low expression. Epiregulin as a selective biomarker requires further evaluation.

    Original languageEnglish
    Pages (from-to)648-655
    Number of pages8
    JournalBritish Journal of Cancer
    Volume110
    Issue number3
    DOIs
    Publication statusPublished - 2014

    Fingerprint Dive into the research topics of 'Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer'. Together they form a unique fingerprint.

  • Cite this

    Jonker, D., Karapetis, C., Harbison, C., O'Callaghan, C., Tu, D., Simes, R., Malone, D., Langer, C., Tebbutt, N., Price, T., Shapiro, J., Siu, L., Wong, R., Bjarnason, G., Moore, M., Zalcberg, J., & Khambata-Ford, S. (2014). Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer. British Journal of Cancer, 110(3), 648-655. https://doi.org/10.1038/bjc.2013.753